毒结清口服液联合VAD方案治疗多发性骨髓瘤疗效观察

Clinical Observation on Dujieqing Oral Liquid and VAD Regimen in the Treatment of Multiple Myeloma

目的:观察毒结清口服液联合VAD方案(长春新碱+阿霉素+地塞米松)治疗多发性骨髓瘤(multiple myeloma,MM)的临床疗效。方法:回顾性分析2015年3月至2020年3月于广西中医药大学第一附属医院治疗的82例MM患者的临床资料,依据治疗方案将患者分为联合组52例和对照组30例,对照组采用VAD方案化疗,联合组采用毒结清口服液联合VAD方案化疗。比较两组患者临床疗效、不良反应发生情况及治疗前后中医证候积分、肾功能指标和实验室指标。结果:两组临床疗效和不良反应总发生率比较,差异均无统计学意义(P>0.05);治疗后联合组中医证候积分、血肌酐(serum creatinine,SCr)、血尿素氮(blood urea nitrogen,BUN)、M蛋白、β2-微球蛋白(β2-microglobulin,β2-MG)、乳酸脱氢酶(lactate dehydrogenase,LDH)水平均低于对照组(P<0.05),血红蛋白(hemoglobin,Hb)水平高于对照组(P<0.05)。结论:毒结清口服液联合VAD方案可有效缓解MM患者临床症状,改善患者肾功能和Hb、M蛋白、β2-MG和LDH水平,且有一定安全性。

Objective:To observe clinical effects of Dujieqing oral liquid combined with VAD regimen(vincristine+doxorubicin+dexamethasone)in the treatment of multiple myeloma(MM).Methods:Clinical data of 82 MM patients admitted to the First Affiliated Hospital of Guangxi University of Chinese Medicine was retrospectively analyzed from March,2015 to March,2020,and they were allocated to 52 cases of the combination group and 30 cases of the control group in accordance with therapeutic regimen,the control group adopted VAD regimen,and the combination group was treated with Dujieqing oral liquid and VAD regimen.To compare clinical effects,the incidences of adverse reactions,TCM syndrome integrals,the indexes of renal function and lab indicators between both groups before and after the treatment.Results:The difference had no statistical meaning in clinical effects,total incidences of adverse reactions between both groups(P>0.05);after the treatment,TCM syndrome integrals,the levels of Scr,BUN,monoclonal protein,β2-MG and LDH of the combination group were lower than those of the control group(P<0.05),the levels of Hb higher than those of the control group(P<0.05).Conclusion:Dujieqing oral liquid combined with VAD regimen could effectively alleviate the clinical symptoms of MM patients,improve the renal function,the levels of serum Hb,M protein,β2-MG and LDH with certain safety.